A Bispecific Nanovehicle Disarms a Biofilm Amyloid Shield for Implant-Related Osteomyelitis Therapy - PubMed
7 hours ago
- #nanovehicle
- #osteomyelitis
- #biofilm
- A bispecific nanovehicle (PPTV@MSa) was developed to treat implant-associated osteomyelitis (IAOM).
- It coencapsulates thymol (Thy) and vancomycin (Van) in alendronate-functionalized polydopamine nanoparticles, camouflaged with a pretreated macrophage membrane for targeted delivery.
- Thymol disarms biofilm amyloid structures by suppressing phenol-soluble modulins, destabilizing the biofilm to enhance vancomycin's effectiveness.
- The nanovehicle uses dual-targeting: macrophage membrane for infection site accumulation and alendronate for bone matrix anchoring upon bacterial toxin disruption.
- In vivo studies confirmed precise targeting and strong antibiofilm efficacy, offering a promising strategy for IAOM therapy.